CLINICAL RELEVANCE: DRUG–DRUG INTERACTION,PHARMACOKINETICS,PHARMACODYNAMICS, AND TOXICITY - Drug Transporters: Molecular Characterization and Role in Drug Disposition - page 862

691. Shiga T, Hashiguchi M, Urae A, Kasanuki H, Rikihisa T. 2000. Effect of cimetidine and
probenecid on pilsicainide renal clearance in humans. Clin Pharmacol Ther 67: 222-228.
692. Kawasaki Y, Kato Y, Sai Y, Tsuji A. 2004. Functional characterization of human organic
cation transporter OCTN1 single-nucleotide polymorphisms in the Japanese population.
J Pharm Sci 93: 2920-2926.
693. Urban TJ, Gallagher RC, Brown C, Castro RA, Lagpacan LL, Brett CM, Taylor TR,
Carlson EJ, Ferrin TE, Burchard EG, Packman S, Giacomini KM. 2006. Functional
genetic diversity in the high-affinity carnitine transporter OCTN2 (SLC22A5). Mol
Pharmacol, Aug 24 [Epub ahead of print].
694. Tang NLS, Ganapathy V, Wu X, Hui J, Seth Pm Yuen PMP, Fok TF, Hjelm NM.
1999. Mutations of OCTN2, an organic cation/carnitine transporter, lead to deficient
cellular carnitine uptake in primary carnitine deficiency. Hum Mol Genet 8: 655-
660.
695. Lahjouji K, Mitchell GA, Qureshi IA. 2001. Carnitine transport by organic cation
transporters and systemic carnitine deficiency. Mol Genet Metab 73: 287-297.
696. Wang Y, Taroni F, Garavaglia B, Longo N. 2000. Functional analysis of mutations in the
OCTN2 transporter causing primary carnitine deficiency: lack of genotype-phenotype
correlation. Hum Mutat 16: 401-407.
697. Wang Y, Korman SH, Ye J, Gargus JJ, Gutman A, Taroni F, Garavaglia B, Longo N. 2001.
Phenotype and genotype variation in primary carnitine deficiency. Genet Med 3: 387-
392.
698. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ,
Ganapathy V. 1999. Functional characteristics and tissue distribution pattern of organic
cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp
Ther 290: 1482-1492.
699. Koizumi A, Nozaki J, Ohura T, Kayo T, Wada Y, Nezu J, Ohashi R, Tamai I, Shoji Y,
Takada G, et al. 1999. Genetic epidemiology of the carnitine transporter OCTN2 gene
in a Japanese population and phenotypic characterization in Japanese pedigrees with
primary systemic carnitine deficiency. Hum Mol Genet 8: 2247-2254.
700. Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH,
Ganapathy V. 2000. Beta-lactam antibiotics as substrates for OCTN2, an organic
cation/carnitine transporter. J Biol Chem 275: 1699-1707.
701. Wagner CA, L ukewille U, Kaltenbach S, Moschen I, Broer A, Risler T, Broer S, Lang
F. 2000. Functional and pharmacological characterization of human Na( + )-carnitine
cotransporter hOCTN2. Am J Physiol Renal Physiol 279: F584-F591.
702. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Yoshimichi S, Shimane M, Tsuji A.
1999. Na( + )-dependent carnitine transport by organic cation transporter (OCTN2): its
pharmacological and toxicological relevance. J Pharmacol Exp Ther 91: 778-784.
703. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A.
1999. Novel membrane transporter OCTN1 mediates multispecific, bidirectional and
pH-dependent transport of organic cations. J Pharmacol Exp Ther 289: 768-773.
704. Yabuuchi H, Tamai I, Nezu J, Sakamoto K, Oku A, Shimane M, Sai Y, Tsuji A.
1999. Novel membrane transporter OCTN1 mediates multispecific, bidirectional and
pH-dependent transport of organic cations. J Pharmacol Exp Ther 289: 768-773.
705. Tein I. 2003. Carnitine transport: pathophysiology and metabolism of known molecular
defects. J Inherit Metab Dis 26: 147-169.